This Week at FDA: New guidances address cancer PROs, neurodevelopmental safety studies, and more

This Week at FDA

This Week at FDAMichael Mezher

GenericsGuidanceMedical DevicesPharmaceuticalsRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)